Amphotericin B Liposomal Tillomed: Uses, Dosage & Side Effects

What Is Amphotericin B Liposomal Tillomed and What Is It Used For?

Amphotericin B liposomal Tillomed contains the active substance amphotericin B, one of the oldest and most effective antifungal agents available in clinical medicine. First isolated from Streptomyces nodosus in the late 1950s, amphotericin B has remained a cornerstone of antifungal therapy for over six decades, particularly for life-threatening invasive fungal infections. However, the conventional formulation (amphotericin B deoxycholate) is associated with significant toxicity, most notably nephrotoxicity and severe infusion-related reactions, which have long limited its clinical utility.

The liposomal formulation represents a major pharmaceutical innovation that addresses these toxicity concerns. In this product, amphotericin B molecules are intercalated within a lipid bilayer composed of hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, cholesterol, and alpha-tocopherol. These liposomes are small, unilamellar vesicles with a mean diameter of less than 100 nanometers. The liposomal encapsulation fundamentally alters the pharmacokinetic behavior of amphotericin B: it reduces direct exposure of the drug to kidney tubular cells and red blood cells, which are primarily responsible for nephrotoxicity and hemolytic reactions respectively. The liposomes preferentially accumulate in tissues of the reticuloendothelial system (liver, spleen, lungs) and at sites of infection, effectively targeting the drug to where it is most needed.

Amphotericin B exerts its antifungal activity by binding to ergosterol, a sterol component of the fungal cell membrane that is analogous to cholesterol in mammalian cells. When amphotericin B binds to ergosterol, it forms transmembrane pores or channels that disrupt the membrane's selective permeability. This leads to leakage of essential intracellular contents, including potassium ions, amino acids, and other small molecules, ultimately causing cell death. The preferential affinity of amphotericin B for ergosterol over cholesterol explains its selective toxicity toward fungi, although some binding to mammalian cholesterol does occur and accounts for dose-limiting side effects.

Amphotericin B has the broadest spectrum of activity of any currently available antifungal agent. It is active against most clinically relevant yeasts and moulds, including Candida species (including many azole-resistant strains), Aspergillus species, Cryptococcus neoformans, Mucor and Rhizopus species (agents of mucormycosis), Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, and Sporothrix schenckii. It also has activity against certain protozoa, notably Leishmania species, which accounts for its use in visceral leishmaniasis.

Amphotericin B liposomal Tillomed is indicated for the following conditions:

• Severe invasive candidiasis: Treatment of systemic Candida infections, including candidemia, disseminated candidiasis, and other deep-seated Candida infections in patients who have not responded to or cannot tolerate first-line azole therapy.
• Invasive aspergillosis: Treatment of invasive pulmonary and disseminated aspergillosis, particularly in immunocompromised patients such as those undergoing hematopoietic stem cell transplantation or receiving intensive chemotherapy for hematological malignancies.
• Cryptococcal meningitis: Treatment of cryptococcal meningoencephalitis in HIV-infected and other immunocompromised patients. WHO guidelines recommend liposomal amphotericin B as a preferred component of induction therapy for cryptococcal meningitis.
• Empirical antifungal therapy: Treatment of presumed fungal infections in febrile neutropenic patients when broad-spectrum antibacterial therapy has failed to resolve fever and a fungal origin is suspected.
• Visceral leishmaniasis (kala-azar): Treatment of visceral leishmaniasis caused by Leishmania donovani and related species, particularly in patients who have not responded to antimonial compounds or in whom antimonials are contraindicated.
• Mucormycosis (zygomycosis): First-line treatment of invasive mucormycosis, a rare but rapidly progressive and often fatal fungal infection caused by fungi of the order Mucorales, which is intrinsically resistant to voriconazole.

What Should You Know Before Receiving Amphotericin B Liposomal Tillomed?

Contraindications

There are specific situations in which Amphotericin B liposomal Tillomed must not be used. Your prescribing physician will carefully evaluate these before initiating treatment.

• Hypersensitivity: Do not receive this medication if you have a known allergy to amphotericin B or to any of the excipients, including hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, cholesterol, alpha-tocopherol, sucrose, disodium succinate hexahydrate, or sodium hydroxide. However, if the treating physician determines that the infection is life-threatening and no suitable alternatives exist, the drug may still be used after careful risk-benefit assessment and with appropriate precautions for managing anaphylaxis.

In clinical practice, true absolute contraindications to liposomal amphotericin B are rare because this drug is typically reserved for serious, life-threatening infections where the benefit of treatment generally outweighs the risks. Nevertheless, careful clinical judgment is required, and alternative antifungal agents should be considered when hypersensitivity is documented.

Warnings and Precautions

Before and during treatment with Amphotericin B liposomal Tillomed, your healthcare team will monitor for the following:

• Nephrotoxicity: Although the liposomal formulation substantially reduces kidney toxicity compared with conventional amphotericin B, nephrotoxicity can still occur, particularly with prolonged use, high cumulative doses, or concurrent use of other nephrotoxic drugs. Serum creatinine, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR) will be monitored regularly. If kidney function deteriorates significantly, your doctor may reduce the dose, interrupt treatment, or switch to an alternative antifungal.
• Electrolyte disturbances: Amphotericin B commonly causes hypokalemia (low potassium) and hypomagnesemia (low magnesium) by increasing renal tubular losses of these electrolytes. Severe hypokalemia can cause dangerous heart rhythm disturbances and muscle weakness. Potassium and magnesium levels will be monitored frequently, and supplementation is often required.
• Infusion-related reactions: Fever, rigors (shaking chills), nausea, vomiting, headache, and hypotension can occur during or shortly after infusion, particularly with the first few doses. These reactions are generally less frequent and less severe with the liposomal formulation than with conventional amphotericin B. Pre-medication with paracetamol (acetaminophen), an antihistamine, or a corticosteroid may be given. A test dose is recommended before the first full infusion.
• Hepatotoxicity: Liver enzyme elevations (AST, ALT, alkaline phosphatase) and hyperbilirubinemia have been reported. Liver function tests will be monitored regularly during treatment.
• Hematological effects: Anemia, thrombocytopenia (low platelets), and leukopenia (low white blood cells) may occur. Regular blood count monitoring is essential, particularly in patients already at risk of bone marrow suppression from underlying disease or concurrent medications.
• Anaphylaxis and severe allergic reactions: Rare but potentially life-threatening anaphylactic or anaphylactoid reactions have been reported. Resuscitation equipment and medication should be immediately available during infusion. If a severe reaction occurs, the infusion must be stopped immediately and the patient should not receive further doses unless the medical team determines that the benefit clearly outweighs the risk.
• Pulmonary toxicity: Acute pulmonary reactions including dyspnea, hypoxemia, and pulmonary infiltrates have been reported, particularly with rapid infusion or when given concurrently with leukocyte transfusions. Allow adequate time between amphotericin B infusion and leukocyte transfusions.

Pregnancy and Breastfeeding

The safety of Amphotericin B liposomal Tillomed during pregnancy has not been established in controlled clinical trials. Conventional amphotericin B has been used in pregnant patients with systemic fungal infections for decades without clear evidence of teratogenicity in humans, and it is generally considered one of the safer antifungal options when treatment of a life-threatening invasive fungal infection is required during pregnancy. However, the liposomal formulation specifically has limited pregnancy data from clinical studies.

The decision to use this medication during pregnancy must be made by the treating physician after carefully weighing the severity and prognosis of the fungal infection against the potential risks to the fetus. Untreated invasive fungal infections carry a very high mortality rate, and in many cases, the benefit of treatment is considered to clearly outweigh the theoretical risks. Animal reproductive toxicity studies with liposomal amphotericin B have shown some evidence of embryotoxicity at high doses, but the relevance of these findings to human pregnancy at therapeutic doses is uncertain.

It is not known whether amphotericin B passes into breast milk. Given the low oral bioavailability of amphotericin B and the serious nature of the conditions for which it is prescribed, a decision must be made whether to discontinue breastfeeding or to continue treatment, taking into account the importance of the medication for the mother.

How Does Amphotericin B Liposomal Tillomed Interact with Other Drugs?

Drug interactions with amphotericin B are clinically significant and can lead to serious adverse effects if not properly managed. The two main mechanisms of interaction are: (1) additive or synergistic toxicity, particularly nephrotoxicity and electrolyte disturbances; and (2) pharmacodynamic interactions where the effects of amphotericin B on electrolytes (especially hypokalemia) amplify the toxicity or alter the efficacy of other drugs. Your healthcare team will carefully review all concurrent medications and adjust treatment as necessary.

Major Interactions

Other Notable Interactions

This list is not exhaustive. Always inform your healthcare team about all medications, supplements, and herbal products you are taking. Drug interaction management is a critical component of safe amphotericin B therapy, and your medical team will adjust treatment regimens accordingly.

What Is the Correct Dosage of Amphotericin B Liposomal Tillomed?

Amphotericin B liposomal Tillomed is administered exclusively as an intravenous infusion in a hospital setting by trained healthcare professionals. The dosing is weight-based (mg per kg of body weight) and varies depending on the indication being treated, the severity of the infection, the patient's clinical response, and tolerability. It is critical to emphasize that the doses described here are specific to the liposomal formulation and must NOT be used for other amphotericin B products.

Adults

Children

The dosing recommendations for children and adolescents are the same as for adults on a mg/kg basis. Children have been included in clinical trials of liposomal amphotericin B, and the pharmacokinetic data support using weight-based dosing without further age-specific adjustment. Neonates and infants may require particularly careful monitoring of kidney function and electrolytes, as their renal physiology is still maturing. The clinical team will adjust dosing based on the child's response and tolerance.

Elderly Patients

No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients are more likely to have pre-existing renal impairment and to be receiving other nephrotoxic or electrolyte-depleting medications, which increases the risk of adverse effects. Baseline and ongoing monitoring of kidney function and electrolytes should be particularly vigilant in this population. The healthcare team may start at the lower end of the dosing range and titrate upward based on response and tolerability.

Renal and Hepatic Impairment

Patients with pre-existing renal impairment can receive liposomal amphotericin B, but require intensified monitoring. The liposomal formulation is generally preferred over conventional amphotericin B in patients with renal compromise because of its reduced nephrotoxic potential. No specific dose adjustment for hepatic impairment is established, but liver function should be monitored regularly. Dose adjustments may be made based on clinical response and tolerability rather than following fixed pharmacokinetic guidelines.

Missed Dose

As Amphotericin B liposomal Tillomed is administered in a hospital setting by healthcare professionals, missed doses are unlikely. If a dose is missed, it should be given as soon as possible; the subsequent dose should not be doubled. The treating physician will decide on the appropriate timing of subsequent doses to maintain adequate antifungal coverage while minimizing toxicity.

Overdose

Overdose with liposomal amphotericin B may result in exaggeration of known adverse effects, particularly cardiorespiratory arrest, renal failure, and severe electrolyte disturbances. There have been reports of cardiac arrest and death following inadvertent overdose, particularly when the liposomal dose was mistakenly prepared using the dosing for the conventional formulation, or vice versa. If an overdose occurs, the infusion must be stopped immediately. Treatment is supportive and symptomatic: monitoring and correction of electrolytes (especially potassium and magnesium), monitoring of cardiac rhythm, assessment and support of renal function, and management of any anaphylactic or severe infusion reactions. There is no specific antidote for amphotericin B. Hemodialysis is not effective in removing amphotericin B from the body.

What Are the Side Effects of Amphotericin B Liposomal Tillomed?

Like all medicines, Amphotericin B liposomal Tillomed can cause side effects, although not everybody experiences them. The side effect profile of the liposomal formulation is substantially more favorable than that of conventional amphotericin B deoxycholate, with significantly lower rates of nephrotoxicity, infusion-related reactions, and electrolyte disturbances. However, this is still a potent medication used to treat serious infections, and a range of adverse effects can occur. Your medical team will monitor you closely throughout treatment.

Side effects are categorized below by how frequently they occur:

Infusion-related reactions (fever, chills, rigors, nausea, vomiting, headache, back pain, hypotension) are among the most commonly observed adverse effects and typically occur during or within the first few hours after the infusion. They are most frequent with the initial doses and tend to diminish in severity with subsequent administrations. Pre-medication with paracetamol (acetaminophen), diphenhydramine or another antihistamine, and/or hydrocortisone can reduce the incidence and severity of these reactions. Slowing the infusion rate may also help.

Nephrotoxicity remains a concern, although at substantially lower rates than with conventional amphotericin B. Clinical trials comparing liposomal amphotericin B with the conventional formulation have consistently demonstrated significantly lower rates of creatinine elevation and severe renal impairment. The AmBiLoad study and the AmBisome pivotal trial both showed nephrotoxicity rates approximately 50–70% lower with the liposomal formulation. Nevertheless, some degree of renal function decline may occur, particularly with prolonged use or high cumulative doses, and regular monitoring remains essential.

Electrolyte disturbances, particularly hypokalemia and hypomagnesemia, result from amphotericin B's effects on renal tubular function. These can be clinically significant and potentially dangerous (hypokalemia can cause cardiac arrhythmias and respiratory muscle weakness), requiring regular monitoring and proactive supplementation. Potassium and magnesium levels should be checked at least every other day during treatment, and intravenous supplementation is frequently required.

How Should You Store Amphotericin B Liposomal Tillomed?

Amphotericin B liposomal Tillomed is a hospital-administered medication, and its storage and handling are managed by trained pharmacy staff. However, understanding the storage requirements is important for ensuring product integrity and patient safety.

Unopened vials: Store in a refrigerator between 2°C and 8°C. Do not freeze. Keep the vials in the original carton to protect from light. Do not use this medicine after the expiry date stated on the carton and vial label.

After reconstitution: The reconstituted concentrate (using sterile water for injections) is chemically and physically stable for up to 24 hours when stored in a refrigerator (2–8°C). From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

After dilution: Once diluted with 5% glucose (dextrose) solution, the infusion should be used within 6 hours at room temperature (up to 25°C) or up to 24 hours if refrigerated. The diluted solution should be inspected visually for particulate matter and discoloration before administration. Do not use if the solution appears cloudy, has precipitated, or contains particles.

Incompatibility: Amphotericin B liposomal Tillomed must NOT be reconstituted or diluted with saline (sodium chloride) solution, as this will cause aggregation of the liposomes and loss of product integrity. It should not be mixed with other intravenous medications or infused through the same line unless the line has been thoroughly flushed with 5% glucose solution beforehand. Use only 5% glucose (dextrose) for dilution.

Do not dispose of any unused medicine via wastewater or household waste. Return any unused product to the hospital pharmacy for proper disposal in accordance with local regulations.

What Does Amphotericin B Liposomal Tillomed Contain?

Understanding the composition of Amphotericin B liposomal Tillomed is important for identifying potential allergens and understanding the formulation technology.

Active substance: Each vial contains 50 mg of amphotericin B, encapsulated within liposomes. After reconstitution with 12 mL of sterile water for injections, the resulting dispersion contains 4 mg/mL of amphotericin B.

Liposomal components:

• Hydrogenated soy phosphatidylcholine (HSPC): A phospholipid derived from soybean lecithin that forms the primary structural component of the liposome bilayer. Patients with soy allergy should inform their healthcare provider, although severe allergic reactions to highly purified soy phospholipids are extremely rare.
• Distearoylphosphatidylglycerol (DSPG): An anionic phospholipid that contributes to liposome membrane stability and provides a negative surface charge that helps prevent liposome aggregation.
• Cholesterol: Incorporated into the liposome bilayer to modulate membrane fluidity and stability, reducing drug leakage during storage and circulation.
• Alpha-tocopherol: Vitamin E, included as an antioxidant to prevent oxidative degradation of the lipid components during storage.

Other excipients:

• Sucrose: Used as a cryoprotectant and bulking agent in the lyophilized powder, protecting the liposome structure during the freeze-drying process.
• Disodium succinate hexahydrate: A buffering agent that maintains the pH of the formulation within an appropriate range.
• Sodium hydroxide: Used for pH adjustment during manufacture.

Appearance: The product is supplied as a yellow to amber lyophilized (freeze-dried) powder in single-use glass vials. After reconstitution with sterile water for injections, it forms a translucent, yellow to amber dispersion. After further dilution with 5% glucose solution, the final infusion solution should appear translucent to slightly opalescent.